{"id":"NCT01532570","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions","officialTitle":"To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2012-02-14","resultsPosted":"2016-12-16","lastUpdate":"2016-12-16"},"enrollment":18,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Behcet's Disease","Behcet Syndrome","Neuro-Behcet's Disease"],"interventions":[{"type":"DRUG","name":"TA-650","otherNames":[]}],"arms":[{"label":"TA-650","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650 in patients with Behcet's disease ( BD ) with special lesions after the administration of TA-650 at a dosage of 5 mg/kg in weeks 0, 2, and 6, then every 8 weeks after week 14 up to week 46.","primaryOutcome":{"measure":"Percentage of Participants With Complete Response at Week 30","timeFrame":"Week 30","effectByArm":[{"arm":"Intestinal BD","deltaMin":54.5,"sd":null},{"arm":"Acute Neuro-BD","deltaMin":0,"sd":null},{"arm":"Chronic Progressive Neuro-BD","deltaMin":100,"sd":null},{"arm":"Vascular BD","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":["27310969"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Double stranded DNA antibody positive","Upper respiratory tract infection","Nasopharyngitis","Enteritis infectious","Gastroenteritis"]}}